Clinical Efficacy of Modified Zhishi Daozhiwan on Slow Transit Constipation

Fang LIU; Xian-peng WEI; Xue-gui TANG

doi:10.13422/j.cnki.syfjx.20192034

您当前的位置：

首页 >

文章列表页 >

Clinical Efficacy of Modified Zhishi Daozhiwan on Slow Transit Constipation

Clinic | 更新时间：2021-04-16

- Clinical Efficacy of Modified Zhishi Daozhiwan on Slow Transit Constipation
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 26, Issue 2, Pages: 92-97(2020)
- 作者机构：
  
  1.川北医学院　附属医院，四川南充　 637001
  2.川北医学院，四川南充　 637001
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20192034
  CLC： R289:R24:R256:R442.2
- Received：23 May 2018，
  
  Published Online：28 June 2019，
  
  Published：20 January 2020
- 稿件说明：
移动端阅览
Fang LIU, Xian-peng WEI, Xue-gui TANG. Clinical Efficacy of Modified Zhishi Daozhiwan on Slow Transit Constipation[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(2): 92-97.
DOI：

Fang LIU, Xian-peng WEI, Xue-gui TANG. Clinical Efficacy of Modified Zhishi Daozhiwan on Slow Transit Constipation[J]. Chinese journal of experimental traditional medical formulae, 2020, 26(2): 92-97. DOI： 10.13422/j.cnki.syfjx.20192034.

摘要

目的：

观察枳实导滞丸加减治疗慢传输型便秘(STC)热积秘证的疗效及对胃肠激素和肠道内菌群的影响。

方法：

将160例患者随机按数字表法分为对照组和观察组。对照组口服麻仁丸，6 g/次，2次/d；枸橼酸莫沙必利分散片，5 mg/次，3次/d。观察组以枳实导滞丸加减内服治疗，1剂/d。两组均连续治疗4周。进行治疗前后便秘主要性状评分和便秘患者症状自评量表(PAC-SYM)评分；记录平均每周自发完全排便次数(SCBM)；进行治疗前后结肠传输试验；进行治疗前后肠道菌群和胃动素(MTL)，血管活性肠肽(VIP)，P物质(SP)，胃泌素(GAS)检测；对治疗后SCBM≥3次患者进行12周随访，计算复发情况。

结果：

经秩和检验分析，观察组临床疗效好于对照组(

＝2.275，

0.05)；治疗后观察组便秘主要症状评分，PAC-SYM各维度评分和PAC-SYM总分均低于对照组(

0.01)；观察组患者在治疗后2，3，4周的SCBM次数均多于对照组(

0.05)；观察组患者在24，48，72 h残留标志物比例均低于对照组(

0.01)；观察组患者肠球菌和肠杆菌计数均低于对照组(

0.01)，双歧杆菌和乳酸杆菌计数均高于对照组(

0.01)；观察组患者GAS，MTL和SP水平均高于对照组，VIP水平低于对照组(

0.01)；观察组复发率为33.85%，低于对照组的57.69%(

＝6.653，

0.05)。

结论：

枳实导滞丸加减治疗STC热积秘证可明显减轻便秘等症状，增加SCBM次数，调节胃肠激素和肠道内菌群，提高结肠传输功能，临床疗效好，并具有复发率低的特点，值得临床使用。

Abstract

Objective:

To observe the clinical efficacy of modified Zhishi Daozhiwan on slow transit constipation (STC) and the effect on gastrointestinal hormones and intestinal flora.

Method:

One hundred and sixty patients were randomly divided into control group and observation group by random number table. Patients in control group got Maren Wan

1-2 pills/time

2 times/days

and mosapride citrate tablets

1 piece/time

3 times/days. Patients in observation group got modified Zhishi Daozhiwan

1 dose/day. A course of treatment was 4 weeks. Before and after treatment

the main symptoms of constipation and patient assessment of constipation symptoms (PAC-SYM) were scored. And times of spontaneous complete bowel movement (SCBM) and colonic transmission test were recorded. And levels of intestinal flora and motilin (MTL)

vasoactive intestinal peptide (VIP)

substance P (SP) and gastrin (GAS) were detected. The 12-week follow-up of patients (SCBM≥3) was recorded

and the relapse of disease was calculated.

Result:

According to rank sum test analysis

the clinical efficacy in observation group was better than that in control group (

=2.275

0.05). After treatment

scores of the main symptoms of constipation

PAC-SYM

and the total score of PAC-SYM were all lower than those in control group (

0.01). At the second

third and fourth weeks after treatment

the times of SCBM were more than those in control group (

0.01). Ratio of residual marker at 24

48 and 72 h was lower than that in control group (

0.01). Count of enterococcus and enterobacter were lower than those in control group (

0.01)

while counts of bifidobacterium and lactobacillus were higher than in control group (

0.01). Levels of GAS

MTL and SP were higher than those in control group

whereas level of VIP was lower than that in control group (

0.01). And relapse rate in observation group was 33.85%

which was lower than 57.69% in control group (

=6.653

0.05).

Conclusion:

Modified Zhishi Daozhiwan can alleviate constipation and other symptoms

increase the number of SCBM

regulate gastrointestinal hormones and intestinal flora

and improve colonic transit function

with a good clinical efficacy and low recurrence rate

so it is worth clinical application.

关键词

Keywords

references

王佩佩，罗雯，禹铮，等．慢性便秘的研究进展 [J]．中国全科医学， 2017 ， 20 ( 3 )： 370 - 374 .

相翠玉，刘洁，张永洲，等．加味四磨汤治疗成人功能性便秘及对肠道神经递质的影响 [J]．中国实验方剂学杂志， 2019 ， 25 ( 2 )： 150 - 155 .

卜佳，许翠萍．慢性便秘和慢病管理 [J]．世界华人消化杂志， 2016 ， 24 ( 30 )： 4162 - 4168 .

范艺缤，唐学贵．唐学贵升清降浊法治疗老年性便秘临证经验探析 [J]．中医药临床杂志， 2017 ， 29 ( 6 )： 811 - 813 .

吴至久，张蜀，唐学贵，等．从气机升降失常论治便秘 [J]．国医论坛， 2017 ， 32 ( 2 )： 21 - 22 .

张洁颖．针刺诊疗慢性便秘荟萃分析 [J]．辽宁中医药大学学报， 2016 ， 18 ( 4 )： 174 - 178 .

李媛，董乃娥，郭玉成．枳实导滞丸对小鼠胃排空和小肠推进的影响 [J]．承德医学院学报， 2008 ， 25 ( 2 )： 212 - 213 .

沈天成，沈乙惠，游春木．枳实导滞汤加减治疗肠道湿热证便秘型肠易激综合征的临床观察 [J]．实用中西医结合临床， 2017 ， 17 ( 8 )： 124 - 125 .

钟仕江，唐学贵．枳实导滞汤加减治疗儿童功能性便秘(食积气滞型)的临床研究 [D]．成都：成都中医药大学， 2018 .

中华医学会消化病学分会胃肠动力组，中华医学会外科学分会结直肠肛门外科学组．中国慢性便秘诊治指南 [J]．胃肠病学， 2013 ， 18 ( 10 )： 605 - 612 .

中华中医药学会脾胃病分会．便秘中医诊疗专家共识意见(2017) [J]．中医杂志， 2017 ， 58 ( 15 )： 1345 - 1349 .

宋玉磊，林征，柏亚妹 . 功能性便秘疗效评估指标的现状与评价 [J]. 中国实用内科杂志， 2016 ， 36 ( 9 )： 813 - 816 .

颜帅，董宏利，乐音子，等．通便汤治疗老年慢传输型便秘多中心、双盲、随机对照临床研究 [J]．中华中医药杂志， 2018 ， 33 ( 3 )： 1171 - 1174 .

张双喜，张相安，安永康．济川煎对老年慢性功能性便秘患者胃肠功能、血清肠神经递质及肠道菌群的影响 [J]．中国实验方剂学杂志， 2018 ， 24 ( 22 )： 169 - 174 .

于阿莉，刘响，安莹莹，等．肠道菌群失调与慢性便秘的研究进展 [J]．国际消化病杂志， 2017 ， 37 ( 2 )： 83 - 86 .

白克运，韩玮玮，王本军，等．附子丁香散加味穴位贴敷对阳虚型慢传输型便秘大鼠血清血管活性肠肽，P物质水平的影响 [J]．山东医药， 2018 ， 58 ( 3 )： 42 - 44 .

王郁金，周永学，张红，等．功能性便秘大鼠在体结肠肌电及血清中胃动素、胃泌素的变化 [J]．陕西中医， 2014 ， 35 ( 9 )： 1255 - 1256 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Rhei Radix et Rhizoma Before and After Steaming with Wine on Intestinal Flora and Immune Environment in Constipation Model Mice

Therapeutic Effect and Mechanism of Yiqi Huoxue Tongbian Prescription on Slow Transit Constipation in Rats

Mechanism of Paeonol in Alleviating Alcohol-induced Liver Injury in Mice Through Regulating SCFAs-GPR43/MAPK Signaling Pathway Mediated by Intestinal Flora

Effect of Huangling Jidu Xizhuo Granules on NLRP3， Intestinal Flora and Short-term Prognosis in Patients with Gout

Related Author

BAI Yaya

TIAN Rui

SHI Yajun

ZHAO Chongbo

SUN Jing

ZHANG Li

YAN Yonggang

TANG Yuping

Related Institution

Shaanxi Engineering Technology Research Center of Chinese Herbal Pieces，Shaanxi Qinling Application Development and Engineering Research Center of Chinese Herbal Medicine，Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine（TCM） for TCM Compatibility， Shaanxi University of Chinese Medicine，Xi′an

Hanlin College，Nanjing University of Chinese Medicine

Gansu University of Chinese Medicine

Northwest Collaborative Innovation Center for Traditional Chinese Medicine（TCM）

Gansu Pharmaceutical Industry Innovation Research Institute

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰